StimGuard Appoints Tom R. Moore as President

Industry Veteran to Lead Global Commercialization For Revolutionary Wireless Device to Alleviate Incontinence Symptoms

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--StimGuard LLC, a privately held, commercial stage medical device company, today announced the appointment of Tom R. Moore as president effective immediately. In this role, Moore will provide strategic leadership and assume responsibility for bringing StimGuard's wirelessly powered microtechnology neurostimulators for the treatment of refractory urgency urinary incontinence as well as overactive bladder syndrome into global commercialization. With more than 18 years of medical device experience, Moore is an ideal candidate to lead the charge for the growth of this revolutionary device, which has the potential to help millions of people who are suffering from incontinence.

"I look forward to leading StimGuard to success, and, most importantly, working to help patients and their physicians find a treatment solution for their urological disorders."
"We are thrilled and honored to have Mr. Moore join the StimGuard team of talented innovators," said Laura Tyler Perryman, StimGuard's Chairman. "His track record of both commercialization success, as well as leading patient enrollment in landmark clinical trials makes him the ideal fit to help StimGuard to achieve widespread global adoption of this wireless treatment option for incontinence."

Moore joins StimGuard from CVRx, a private company that developed proprietary active implantable technology for the treatment of high blood pressure and heart failure. As Vice President of Sales Operations and Market Development he was responsible for global clinical study enrollment, market development, and commercialization of Barostim Therapy. Moore also has an extensive background working with established international companies, including Medtronic, the world's largest standalone medical technology development company specializing in neurological, urology and gastroenterology.

"The StimGuard wireless product platform is a highly innovative, disruptive technological breakthrough," said Moore. "I look forward to leading StimGuard to success, and, most importantly, working to help patients and their physicians find a treatment solution for their urological disorders."

Moore holds a master's degree from The Carlson School of Management at the University of Minnesota and bachelor's degree in Business from the University of Colorado.

StimGuard products are not approved for sale or commercial distribution, and are limited to investigational use only. For more information about the StimGuard clinical trials, which are testing refractory urgency urinary incontinence as well as overactive bladder syndrome indications, please visit www.stimguard.com or www.clinicaltrials.gov.

About StimGuard

StimGuard is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, implantable, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. StimGuard's goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urinary management. www.stimguard.com

Contacts

Media Contacts:
Glodow Nead Communications
Jenna Hudson, Evan Nicholson or Sonia Sparks, 415-394-6500
[email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.